NSUNs-driven dysregulation: the next frontier in targeted cancer therapy?
Year: 2025
Type: review
Language: en
Topic: RNA modifications and cancer
Authors and affiliations:
raw_author_name: Yingqi Zhao
raw_affiliation_strings: Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China
Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China
raw_author_name: Yuying Zhang
raw_affiliation_strings: Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China
Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China
raw_author_name: Haonan Zhou
raw_affiliation_strings: Hepatobiliary Surgery Department, First Hospital of China Medical University, Shenyang, Liaoning Province, PR China
raw_author_name: Lei Zhang
raw_affiliation_strings: Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China
Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China
raw_author_name: Jinyu Guo
raw_affiliation_strings: Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China
Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China
raw_author_name: Yue Tan
raw_affiliation_strings: Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China
Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China
raw_author_name: Ting Wu
raw_affiliation_strings: Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China
Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China
raw_author_name: Yi Peng
raw_affiliation_strings: Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China
Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China
raw_author_name: Ying Che
raw_affiliation_strings: Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China
Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China
raw_author_name: Zhanlei Pei
raw_affiliation_strings: Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China
Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China
raw_author_name: Jun Li
raw_affiliation_strings: Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China
Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China
raw_author_name: Boshi Fu
raw_affiliation_strings: Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China
Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China
raw_author_name: Minjie Wei
raw_affiliation_strings: Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China. mjwei@cmu.edu.cn
Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China. mjwei@cmu.edu.cn
Shenyang Kangwei Medical Laboratory Analysis Co. LTD, Liaoning Province, Shenyang, PR China. mjwei@cmu.edu.cn
raw_author_name: Gang Wu
raw_affiliation_strings: Hepatobiliary Surgery Department, First Hospital of China Medical University, Shenyang, Liaoning Province, PR China. gangw@cmu.edu.cn
raw_author_name: Xiaoyun Hu
raw_affiliation_strings: Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China. huxy2022@cmu.edu.cn
Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China. huxy2022@cmu.edu.cn
Scientific experimental center, School of Pharmacy, China Medical University, Shenyang, PR China. huxy2022@cmu.edu.cn
raw_author_name: Huizhe Wu
raw_affiliation_strings: Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China. wuhz@cmu.edu.cn
Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China. wuhz@cmu.edu.cn
Scientific experimental center, School of Pharmacy, China Medical University, Shenyang, PR China. wuhz@cmu.edu.cn